Novo Nordisk’s next-gen obesity drug stumbles in comparison study The results add to the challenges facing the one-time leader in the weight loss market

https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/ By Andrew JosephFeb. 23, 2026 Europe Correspondent